Mast Cell Biology pp 47-60

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 716)

Mast Cell Apoptosis and Survival

  • Maria Ekoff
  • Gunnar Nilsson

Abstract

Mast cells are enigmatic cells that are recognized as critical components of our immune system. They are strategically localized at the host/environment interface, display a long lifespan once situated in tissues and have the ability to produce, store and upon activation, release immuno-regulatory molecules. In specific acute and chronic conditions, mast cell accumulation, activation and release of mediators are important for the initiation and perpetuation of the inflammation associated with these disease states. During the past decade, regulatory pathways for mast cell survival have been elucidated, which have, in part, helped to explain the increased number and survival of mast cells observed during inflammatory reactions associated with, e.g., the allergic response. One key group of regulators involved in cell survival and apoptosis is the Bcl-2 family of proteins. The Bcl-2 family consists of pro- and anti-apoptotic members, where the balance between these members determines cellular fate via protein-protein interactions. In this chapter, we will discuss the regulation of mast cell apoptosis and survival and how understanding the mechanisms by which Bcl-2 family members regulate mast cell survival could lead to the identification of key proteins that affect the severity of inflammation. This knowledge could be used to develop treatments for mast cell disorders such as mastocytosis and other inflammatory diseases where mast cells are involved.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Leslie M. Mast cells show their might. Science 2007; 317:614–616.PubMedGoogle Scholar
  2. 2.
    Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol 2004; 4:787–799.PubMedGoogle Scholar
  3. 3.
    Dawicki W, Marshall JS. New and emerging roles for mast cells in host defence. Curr Opin Immunol 2007; 19:31–38.PubMedGoogle Scholar
  4. 4.
    Knight PA, Wright SH, Lawrence CE et al. Delayed expulsion of the nematode Trichinella spiralis in mice lacking the mucosal mast cell-specific granule chymase, mouse mast cell protease-1. J Exp Med 2000; 192:1849–1856.PubMedGoogle Scholar
  5. 5.
    Secor VH, Secor WE, Gutekunst CA et al. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 2000; 191:813–822.PubMedGoogle Scholar
  6. 6.
    Maruotti N, Crivellato E, Cantatore FP et al. Mast cells in rheumatoid arthritis. Clin Rheumatol 2007; 26:1–4.PubMedGoogle Scholar
  7. 7.
    Grimbaldeston MA, Nakae S, Kalesnikoff J et al. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 2007; 8:1095–1104.PubMedGoogle Scholar
  8. 8.
    Brightling CE, Bradding P, Symon FA et al. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346:1699–1705.PubMedGoogle Scholar
  9. 9.
    Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006; 117:1277–1284.PubMedGoogle Scholar
  10. 10.
    Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004; 25:235–241.PubMedGoogle Scholar
  11. 11.
    Soucek L, Lawlor ER, Soto D et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007; 13:1211–1218.PubMedGoogle Scholar
  12. 12.
    Huang B, Lei Z, Zhang GM et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 2008; 112:1269–1279.PubMedGoogle Scholar
  13. 13.
    Kirshenbaum AS, Kessler SW, Goff JP et al. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 1991; 146:1410–1415.PubMedGoogle Scholar
  14. 14.
    Kitamura Y, Shimada M, Hatanaka K et al. Development of mast cells from grafted bone marrow cells in irradiated mice. Nature 1977; 268:442–443.PubMedGoogle Scholar
  15. 15.
    Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77:1033–1079.Google Scholar
  16. 16.
    Kitamura Y. Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol 1989; 7:59–76.PubMedGoogle Scholar
  17. 17.
    Enerback L. Mast cells in rat gastrointestinal mucosa. I. Effects of fixation. Acta Pathol Microbiol Scand 1966; 66:289–302.PubMedGoogle Scholar
  18. 18.
    Aldenborg F, Enerback L. Thymus dependence of connective tissue mast cells: a quantitative cytofluorometric study of the growth of peritoneal mast cells in normal and athymic rats. Int Arch Allergy Appl Immunol 1985; 78:277–282.PubMedGoogle Scholar
  19. 19.
    Irani AA, Schechter NM, Craig SS et al. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA 1986; 83:4464–4468.PubMedGoogle Scholar
  20. 20.
    Nilsson G, Costa JJ, Metcalfe DD. Mast cells and basophils. In: Gallin JI, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. 3rd ed.. Philadelphia: Lippincott Williams and Wilkins; 1999:97–117.Google Scholar
  21. 21.
    Irani AM, Craig SS, DeBlois G et al. Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T-lymphocyte function. J Immunol 1987; 138:4381–4386.PubMedGoogle Scholar
  22. 22.
    Friend DS, Ghildyal N, Austen KF et al. Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J Cell Biol 1996; 135:279–290.PubMedGoogle Scholar
  23. 23.
    Lee YM, Jippo T, Kim DK et al. Alteration of protease expression phenotype of mouse peritoneal mast cells by changing the microenvironment as demonstrated by in situ hybridization histochemistry. Am J Pathol 1998; 153:931–936.PubMedGoogle Scholar
  24. 24.
    Friend DS, Ghildyal N, Gurish MF et al. Reversible expression of tryptases and chymases in the jejunal mast cells of mice infected with Trichinella spiralis J Immunol 1998; 160:5537–5545.PubMedGoogle Scholar
  25. 25.
    Boyce JA. Mast cells: beyond IgE. J Allergy Clin Immunol 2003; 111:24–32; quiz 33.PubMedGoogle Scholar
  26. 26.
    Robinson DS, Hamid Q, Jacobson M et al. Evidence for Th2-type T helper cell control of allergic disease in vivo. Springer Semin Immunopathol 1993; 15:17–27.PubMedGoogle Scholar
  27. 27.
    Gibson PG, Allen CJ, Yang JP et al. Intraepithelial mast cells in allergic and nonallergic asthma. Assessment using bronchial brushings. Am Rev Respir Dis 1993; 148:80–86.PubMedGoogle Scholar
  28. 28.
    Pesci A, Bertorelli G, Gabrielli M et al. Mast cells in fibrotic lung disorders. Chest 1993; 103:989–996.PubMedGoogle Scholar
  29. 29.
    Garriga MM, Friedman MM, Metcalfe DD. A survey of the number and distribution of mast cells in the skin of patients with mast cell disorders. J Allergy Clin Immunol 1988; 82:425–432.PubMedGoogle Scholar
  30. 30.
    Malone DG, Wilder RL, Saavedra-Delgado AM et al. Mast cell numbers in rheumatoid synovial tissues. Correlations with quantitative measures of lymphocytic infiltration and modulation by antiinflammatory therapy. Arthritis Rheum 1987; 30:130–137.PubMedGoogle Scholar
  31. 31.
    Molin D, Edstrom A, Glimelius I et al. Mast cell infiltration correlates with poor prognosis in Hodgkin’s lymphoma. Br JHaematol. 2002; 119:122–124.Google Scholar
  32. 32.
    Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267:1456–1462.PubMedGoogle Scholar
  33. 33.
    Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol 2005; 84:627–639.PubMedGoogle Scholar
  34. 34.
    Mahoney JA, Rosen A. Apoptosis and autoimmunity. Curr Opin Immunol 2005; 17:583–588.PubMedGoogle Scholar
  35. 35.
    Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5:897–907.PubMedGoogle Scholar
  36. 36.
    Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33:29–55.PubMedGoogle Scholar
  37. 37.
    Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309–1312.PubMedGoogle Scholar
  38. 38.
    Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2:647–656.PubMedGoogle Scholar
  39. 39.
    Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001; 26:61–66.PubMedGoogle Scholar
  40. 40.
    Salvesen GS, Duckett CS. IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol 2002; 3:401–410.PubMedGoogle Scholar
  41. 41.
    Shiozaki EN, Shi Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 2004; 29:486–494.PubMedGoogle Scholar
  42. 42.
    Strasser A, Harris AW, Huang DC et al. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 1995; 14:6136–6147.PubMedGoogle Scholar
  43. 43.
    Li H, Zhu H, Xu CJ et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94:491–501.PubMedGoogle Scholar
  44. 44.
    Huang DC, Strasser A. BH3-Only proteins-essential initiators of apoptotic cell death. Cell 2000; 103:839–842.PubMedGoogle Scholar
  45. 45.
    Chen L, Willis SN, Wei A et al. Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Mol Cell 2005; 17:393–403.PubMedGoogle Scholar
  46. 46.
    Kuwana T, Bouchier-Hayes L, Chipuk JE et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17:525–535.PubMedGoogle Scholar
  47. 47.
    Cheng EH, Wei MC, Weiler S et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8:705–711.PubMedGoogle Scholar
  48. 48.
    Zong WX, Lindsten T, Ross AJ et al. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001; 15:1481–1486.PubMedGoogle Scholar
  49. 49.
    Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007; 19:488–496.PubMedGoogle Scholar
  50. 50.
    Baell JB, Huang DC. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol 2002; 64:851–863.PubMedGoogle Scholar
  51. 51.
    Kitamura Y, Go S. Decreased production of mast cells in S1/S1d anemic mice. Blood 1979; 53:492–497.PubMedGoogle Scholar
  52. 52.
    Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978; 52:447–452.PubMedGoogle Scholar
  53. 53.
    Grimbaldeston MA, Chen CC, Piliponsky AM et al. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005; 167:835–848.PubMedGoogle Scholar
  54. 54.
    Finotto S, Mekori YA, Metcalfe DD. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J Clin Invest 1997; 99:1721–1728.PubMedGoogle Scholar
  55. 55.
    Mekori YA, Oh CK, Metcalfe DD. IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand. J Immunol 1993; 151:3775–3784.PubMedGoogle Scholar
  56. 56.
    Iemura A, Tsai M, Ando A et al. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol 1994; 144:321–328.PubMedGoogle Scholar
  57. 57.
    Juurikivi A, Sandier C, Lindstedt KA et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis 2005; 64:1126–1131.PubMedGoogle Scholar
  58. 58.
    Möller C, Alfredsson J, Engström M et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood 2005; 106:1330–1336.PubMedGoogle Scholar
  59. 59.
    Biswas SC, Greene LA. Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation. J Biol Chem 2002; 277:49511–49516.PubMedGoogle Scholar
  60. 60.
    Ley R, Balmanno K, Hadfield K et al. Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim. J Biol Chem 2003; 278:18811–11816.PubMedGoogle Scholar
  61. 61.
    Luciano F, Jacquel A, Colosetti P et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22:6785–6793.PubMedGoogle Scholar
  62. 62.
    Alfredsson J, Puthalakath H, Martin H et al. Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-X(L) upon IgE-receptor activation. Cell Death Differ 2005; 12:136–144.PubMedGoogle Scholar
  63. 63.
    Ekoff M, Kaufmann T, Engstrom M et al. The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 2007; 110:3209–3217.PubMedGoogle Scholar
  64. 64.
    Lindsten T, Ross AJ, King A et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000; 6:1389–1399.PubMedGoogle Scholar
  65. 65.
    Knudson CM, Tung KS, Tourtellotte WG et al. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995; 270:96–99.PubMedGoogle Scholar
  66. 66.
    Rathmell JC, Lindsten T, Zong WX et al. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol 2002; 3:932–939.PubMedGoogle Scholar
  67. 67.
    Maurer M, Tsai M, Metz M et al. A role for Bax in the regulation of apoptosis in mouse mast cells. J Invest Dermatol 2000; 114:1205–1206.PubMedGoogle Scholar
  68. 68.
    Karlberg M, Ekoff M, Labi V et al. Pro-apoptotic Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell apoptosis. Cell Death Dis 2010;e43.Google Scholar
  69. 69.
    Marsden VS, O’Connor L, O’Reilly LA et al. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 2002; 419:634–637.PubMedGoogle Scholar
  70. 70.
    Marsden VS, Kaufmann T, O’Reilly LA et al. Apaf-1 and caspase-9 are required for cytokine withdrawal-induced apoptosis of mast cells but dispensable for their functional and clonogenic death. Blood 2006; 107:1872–1877.PubMedGoogle Scholar
  71. 71.
    Bouillet P, Metcalf D, Huang DC et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis and to preclude autoimmunity. Science 1999; 286:1735–1738.PubMedGoogle Scholar
  72. 72.
    Coultas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 2003; 13:115–123.PubMedGoogle Scholar
  73. 73.
    Hamasaki A, Sendo F, Nakayama K et al. Accelerated neutrophil apoptosis in mice lacking A1-a, a subtype of the bcl-2-related A1 gene. J Exp Med 1998; 188:1985–1992.PubMedGoogle Scholar
  74. 74.
    Xiang Z, Ahmed AA, Moller C et al. Essential role of the prosurvival bcl-2 homologue Al in mast cell survival after allergic activation. J Exp Med 2001; 194:1561–1569.PubMedGoogle Scholar
  75. 75.
    Rinkenberger JL, Horning S, Klocke B et al. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev 2000; 14:23–27.PubMedGoogle Scholar
  76. 76.
    Motoyama N, Wang F, Roth KA et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995; 267:1506–1510.PubMedGoogle Scholar
  77. 77.
    Nakayama K, Nakayama K, Negishi I et al. Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease and lymphocytopenia. Proc Natl Acad Sci USA 1994; 91:3700–3704.PubMedGoogle Scholar
  78. 78.
    Moller C, Karlberg M, Abrink M et al. Bcl-2 and Bcl-XL are indispensable for the late phase of mast cell development from mouse embryonic stem cells. Exp Hematol 2007; 35:385–393.PubMedGoogle Scholar
  79. 79.
    Cohen-Saidon C, Nechushtan H, Kahlon S et al. A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival. Blood 2003; 102:2506–2512.PubMedGoogle Scholar
  80. 80.
    Hartmann K, Wagelie-Steffen AL, von Stebut E et al. Fas (CD95, APO-1) antigen expression and function in murine mast cells. J Immunol 1997; 159:4006–4014.PubMedGoogle Scholar
  81. 81.
    Berent-Maoz B, Piliponsky AM, Daigle I et al. Human mast cells undergo TRAIL-induced apoptosis. J Immunol 2006; 176:2272–2278.PubMedGoogle Scholar
  82. 82.
    Kobayasi T, Asboe-Hansen G. Degranulation and regranulation of human mast cells. An electron microscopic study of the whealing reaction in urticaria pigmentosa. Acta Derm Venereol 1969; 49:369–381.PubMedGoogle Scholar
  83. 83.
    Dvorak AM, Schleimer RP, Lichtenstein LM. Morphologic mast cell cycles. Cell Immunol 1987; 105:199–204.PubMedGoogle Scholar
  84. 84.
    Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002; 2:773–786.PubMedGoogle Scholar
  85. 85.
    Kitaura J, Xiao W, Maeda-Yamamoto M et al. Early divergence of Fc epsilon receptor I signals for receptor up-regulation and internalization from degranulation, cytokine production and survival. J Immunol 2004; 173:4317–4323.PubMedGoogle Scholar
  86. 86.
    Yoshikawa H, Nakajima Y, Tasaka K. Glucocorticoid suppresses autocrine survival of mast cells by inhibiting IL-4 production and ICAM-1 expression. J Immunol 1999; 162:6162–6170.PubMedGoogle Scholar
  87. 87.
    Kalesnikoff J, Huber M, Lam V et al. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity. 2001; 14:801–811.PubMedGoogle Scholar
  88. 88.
    Berent-Maoz B, Salemi S, Mankuta D et al. TRAIL mediated signaling in human mast cells: the influence of IgE-dependent activation. Allergy 2008; 63:333–340.PubMedGoogle Scholar
  89. 89.
    Xiao W, Nishimoto H, Hong H et al. Positive and negative regulation of mast cell activation by Lyn via the FcepsilonRI. J Immunol 2005; 175:6885–6892.PubMedGoogle Scholar
  90. 90.
    Yamasaki S, Ishikawa E, Kohno M et al. The quantity and duration of FcRgamma signals determine mast cell degranulation and survival. Blood 2004; 103:3093–3101.PubMedGoogle Scholar
  91. 91.
    Ekoff M, Strasser A, Nilsson G. FcepsilonRI aggregation promotes survival of connective tissue-like mast cells but not mucosal-like mast cells. J Immunol 2007; 178:4177–4183.PubMedGoogle Scholar
  92. 92.
    Igarashi Y, Goldrich MS, Kaliner MA et al. Quantitation of inflammatory cells in the nasal mucosa of patients with allergic rhinitis and normal subjects. J Allergy Clin Immunol 1995; 95:716–725.PubMedGoogle Scholar
  93. 93.
    Möller C, Xiang Z, Nilsson G. Activation of mast cells by immunoglobulin E-receptor cross-linkage, but not through adenosine receptors, induces A1 expression and promotes survival. Clin Exp Allergy 2003; 33:1135–1140.PubMedGoogle Scholar
  94. 94.
    Xiang Z, Moller C, Nilsson G. IgE-receptor activation induces survival and Bfl-1 expression in human mast cells but not basophils. Allergy 2006; 61:1040–1046.PubMedGoogle Scholar
  95. 95.
    Alfredsson J, Möller C, Nilsson G. IgE-receptor activation of mast cells regulates phosphorylation and expression of forkhead and Bcl-2 family members. Scand J Immunol 2006; 63:1–6.PubMedGoogle Scholar
  96. 96.
    Herold MJ, Zeitz J, Pelzer C et al. The stability and anti-apoptotic function of A1 are controlled by its C terminus. J Biol Chem 2006; 281:13663–13671.PubMedGoogle Scholar
  97. 97.
    Valent P, Akin C, Sperr WR et al. Mastocytosis: pathology, genetics and current options for therapy. Leuk Lymphoma 2005; 46:35–48.PubMedGoogle Scholar
  98. 98.
    Longley BJ, Tyrrell L, Lu SZ et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12:312–314.PubMedGoogle Scholar
  99. 99.
    Longley BJ, Jr., Metcalfe DD, Tharp M et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96:1609–1614.PubMedGoogle Scholar
  100. 100.
    Nagata H, Worobec AS, Oh CK et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92:10560–10564.PubMedGoogle Scholar
  101. 101.
    Aichberger KJ, Gleixner KV, Mirkina I et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 2009; 114:5342–5351.PubMedGoogle Scholar
  102. 102.
    Aichberger KJ, Mayerhofer M, Gleixner KV et al. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 2007; 109:3031–3041.PubMedGoogle Scholar
  103. 103.
    Cervero C, Escribano L, San Miguel JF et al. Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. Am J Hematol 1999; 60:191–195.PubMedGoogle Scholar
  104. 104.
    Baghestanian M, Jordan JH, Kiener HP et al. Activation of human mast cells through stem cell factor receptor (KIT) is associated with expression of bcl-2. Int Arch Allergy Immunol 2002; 129:228–236.PubMedGoogle Scholar
  105. 105.
    Hartmann K, Artuc M, Baldus SE et al. Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis. Am J Pathol 2003; 163:819–826.PubMedGoogle Scholar
  106. 106.
    Oltersdorf T, Elmore SW, Shoemaker AR et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677–681.PubMedGoogle Scholar
  107. 107.
    van Delft MF, Wei AH, Mason KD et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10:389–399.Google Scholar
  108. 108.
    Konopleva M, Contractor R, Tsao T et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10:375–388.PubMedGoogle Scholar
  109. 109.
    Tahir SK, Yang X, Anderson MG et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67:1176–1183.PubMedGoogle Scholar
  110. 110.
    Chen S, Dai Y, Harada H et al. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67:782–791.PubMedGoogle Scholar
  111. 111.
    Lin X, Morgan-Lappe S, Huang X et al. ’seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007; 26:3972–3979.PubMedGoogle Scholar
  112. 112.
    Smits C, Czabotar PE, Hinds MG et al. Structural plasticity underpins promiscuous binding of the prosurvival protein Al. Structure 2008; 16:818–829.PubMedGoogle Scholar
  113. 113.
    Herman MD, Nyman T, Welin M et al. Completing the family portrait of the anti-apoptotic Bcl-2 proteins: crystal structure of human Bfl-1 in complex with Bim. FEBS Lett 2008; 582:3590–3594.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2011

Authors and Affiliations

  • Maria Ekoff
    • 1
  • Gunnar Nilsson
    • 1
  1. 1.Clinical Immunology and Allergy, Department of MedicineKarolinska InstitutetStockholmSweden

Personalised recommendations